Enicepatide (CT-388)
Awaiting review, BioHarmony verdict
Not yet scored. Queued for review; until then rely on the status and sources below.
What is Enicepatide (CT-388)?
Roche describes enicepatide, formerly CT-388, as an investigational GLP-1 and GIP dual receptor agonist. Phase 3 studies are now registered and recruiting, and there is no FDA-approved enicepatide product.
Saved on this device only.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Enicepatide (CT-388) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established
Primary sources
- Roche obesity portfolio update at ADA 2026 Roche,
- Phase 3 study of enicepatide (RO7795068) in obesity or overweight and type 2 diabetes ClinicalTrials.gov, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.